Immuntherapie beim Mammakarzinom

Das Mammakarzinom ist die Hauptursache für krebsbedingte Todesfälle bei Frauen weltweit. Mit intensiver Forschung wurde die Therapie über die letzten Jahrzehnte immer tumorspezifischer weiterentwickelt. Ein neuer vielversprechender Ansatz ist die Immuntherapie. Doch welche Therapieoptionen verstecken sich hinter diesem Überbegriff, welche Therapeutika werden bereits beim Mammakarzinom eingesetzt und welche Optionen sind noch in der Entwicklung?

Schlüsselwörter

Mammakarzinom - onkologische Immuntherapie - Checkpoint-Inhibitoren - PD-1 - PD-L1 - Nebenwirkungen

• Literatur

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
• 2 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-1168
• 3 Deutsches Krebsforschungszentrum. Brustkrebs: Risiken und Vorbeugung. 2021 Zugriff am 30. Januar 2023 unter: https://www.krebsinformationsdienst.de/tumorarten/brustkrebs/risiko-vorbeugen.php
• 4 Curigliano G, Burstein HJ, Winer EP. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-1712
• 5 Arbeitsgemeinschaft Gynäkologische Onkologie e.V.. AGO-Empfehlungen. 2021 Zugriff am 30. Januar 2023 unter: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
• 6 Eggermont AM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer 2011; 7: 2150-2157
• 7 Ali HR, Glont SE, Blows FM. et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015; 26: 1488-1493
• 8 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108-2121
• 9 Miles D, Gligorov J, André F. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021; 32: 994-1004
• 10 Cortes J, Cescon DW, Rugo HS. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817-1828
• 11 Postow MA, Sidlow R, Hellmann MD. Immune-related adverse Events associated with immune checkpoint blockade. N Engl J Med 2018; 378: 158-168
• 12 Iwama S, De Remigis A, Callahan MK. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Translat Med 2014; 6: 230ra245
• 13 Roche. Aktuelle Fachinformation TECENTRIQ® 840 mg/1.200 mg. 2021 Zugriff am 30. Januar 2023 unter: https://media.gelbe-liste.de/documents/neueinfuehrung-tecentriq.pdf
• 14 German Breast Group. NCI Common Terminology Criteria for Adverse Events (CTCAE) – GBG. Zugriff am 30. Januar 2023 unter: https://www.gbg.de/de/rechner/ctcae.php
• 15 Eigentler TK, Hassel JC, Berking C. et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Rev 2016; 45: 7-18
• 16 Brahmer JR, Lacchetti C, Schneider BJ. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768
• 17 Haanen J, Carbonnel F, Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 04) iv119-iv142
• 18 Corti C, Giachetti P, Eggermont AMM. et al. Therapeutic vaccines for breast cancer: Has the time finally come?. Eur J Cancer 2021; 160: 150-174
• 19 Clifton GT, Hale D, Vreeland TJ. et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer. Clin Cancer Research 2020; 26: 2515-2523